ArticleBMC cardiovascular disorders2024
The association of neutrophil-to-lymphocyte ratio with cardiovascular and all-cause mortality among the metabolic syndrome population.
Article in BMC cardiovascular disorders, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- A body roundness index (BRI)-based predictive model for metabolic syndrome in perimenopausal and postmenopausal women-from a cross-sectional machine learning study to a longitudinal dynamic assessment.Annals of medicine · 2026Article
- Age-Dependent Inflammatory, Lipid, and Echocardiographic Phenotypes in Acute Myocardial Infarction: Associations with In-Hospital Adverse Clinical Events.Biomedicines · 2026Article
- Hematological, biochemical and hormonal profiles in dogs with obesity-related metabolic disorder.The Journal of veterinary medical science · 2026Article
- Association Between Neutrophil-to-Lymphocyte Ratio and Mortality Risk Among Patients With Hyperlipidemia Across Different Glycemic Status: A Longitudinal Cohort Study From NHANES 1999-2018.Reviews in cardiovascular medicine · 2026Article
- Metabolic syndrome necroptosis: disease implications and therapeutic targeting.Journal of physiology and biochemistry · 2026Review
- Vitamin D status and Its association with haematological inflammatory indices and cardiometabolic risk profiles: a retrospective cross-sectional study.Frontiers in cardiovascular medicine · 2026Article
- Prognostic Value of the Neutrophil-to-Lymphocyte Ratio for All-Cause Mortality in Patients With Cardiovascular-Kidney-Metabolic Stage 4.Mediators of inflammation · 2026Article
- Prognostic Utility of the Cytokine Profile for Predicting Major Adverse Cardiovascular Events in Acute Myocardial Infarction Following Percutaneous Coronary Intervention.International journal of general medicine · 2026Article
- Cross-sectional mediation analysis of systemic inflammation in the association between serum uric acid and diabetic kidney disease: Evidence from NHANES 1999-2018.Metabolism open · 2025Article
- Observational
- Platelet-to-Lymphocyte and Glucose-to-Lymphocyte Ratios as Prognostic Markers in Hospitalized Patients with Acute Coronary Syndrome.Journal of cardiovascular development and disease · 2025Article
- Evaluation and comparison of inflammatory and insulin resistance indicators on recurrent cardiovascular events in patients undergoing percutaneous coronary intervention: a single center retrospective observational study.Diabetology & metabolic syndrome · 2025Article
- Article
- Association Between NLR, MLR and Stroke Incidence, All-Cause Mortality Among Low-Income Aging Populations: A Prospective Cohort Study.Journal of inflammation research · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundThe neutrophil-to-lymphocyte ratio (NLR) has emerged as a novel inflammatory marker related to disease prognosis, this study aimed to evaluate the association between NLR and mortality in metabolic syndrome (MetS) patients.
methodsThis study used data from 13,156 participants with MetS, derived from the National Health and Nutrition Examination Survey from 1999 to 2020. The NLR was calculated, and its associations with cardiovascular disease (CVD) mortality and all-cause mortality were assessed by multivariate Cox regression, restricted cubic spline and Kaplan-Meier curves. The study performed subgroup analyses to validate the robustness of the findings in different populations. The predictive ability of NLR was evaluated using time-dependent receiver operating characteristic curve. The indirect impact of eGFR was explored by mediation analysis.
resultsAs NLR values increased, there was an obvious rise in the risk of mortality in MetS. The fully adjusted continuous model revealed a 16.0%, 14.4% elevated risk of CVD mortality (HR = 1.160; 95% CI: 1. 090-1.234, p < 0.0001) and all-cause mortality (HR = 1.144; 95% CI: 1. 086-1.206, p < 0.0001), respectively, with each one-unit increment in NLR. Comparing the highest to the lowest quartile of NLR, the top quartile exhibited a significantly increased risk of CVD mortality (HR = 2. 447; 95% CI: 1. 561-3. 836, p < 0.0001), and all-cause mortality (HR = 1. 53; 95% CI: 1. 188-1. 972, p = 0.001) among individuals with MetS. Subgroup analyses substantiated the stability of these associations in most populations. The curve under area for the 3, 5, and 10 years were 0.650, 0.716, and 0.645 for CVD mortality, and 0.746, 0.688, and 0.635 for all-cause mortality. Significantly, the eGFR acted as an intermediary in the relationship of NLR with CVD mortality and all-cause mortality, accounting for 9.85% and 9.86% of the effect, respectively.
conclusionThe NLR served as a significant indicator for assessing the risk of mortality in the MetS population. Consequently, we recommended the regular assessment of NLR in MetS populations as a potentially advantageous method for evaluating their risk of mortality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.